Adding exogenous Sp1 to a HeLa nuclear extract enhanced the Sp1-containing complex but had no effect on the Prox complex. These studies show that Sp1 can be targeted to a non-Sp1 site in the human NF(H) promoter through protein/protein interactions with a distinct sequence specific DNA-blnding protein.
INTRODUCTION
Transcription initiation by RNA polymerase II requires an array of cellular factors. Many factors are sequence specific DNAbinding proteins which enter the transcription complex through their DNA-binding activity (1) . However other factors lack DNAbinding activity and instead enter the transcription complex through proteui/protein interactions. Except for the TATA box binding factor (TBP/TF11D) all of the general initiation factors utilize this latter mechanism (2) . Yet components of the transcription complex other than the general initiation factors may be recruited by protein/protein interactions as well. The adenovirus Ela protein activates viral gene transcription even though it lacks DNA-binding activity. One mechanism of targeting Ela to viral promoters is through Ela's interaction with a cellular DNA-binding protein ATF-2 (3) . Similarly the Herpes virus transcription factor VP-16 interacts with VP-16 responsive promoters through protein/protein interactions with cellular factors rather than by DNA-binding (4) . How frequently cellular promoters utilize this mechanism to recruit transcription factors other than the general initiation factors is not known. Additionally it is not known how frequently sequence specific DNA-binding proteins are recruited through protein/protein interactions rather than DNA-binding. Spl is one of the best studied cellular transcription factors (5) . Spl binds DNA in a sequence specific manner interacting with sequences such as GGGGCGGGG (GC boxes) and some closely related sequences found in many viral and cellular promoters (6) . Transcriptional activation by Spl also requires non-DNA binding co-activators (7, 8) . Currently Spl is believed to enter transcription complexes exclusively through its DNA-binding activity. Here we show an alternative mechanism which targets Spl to the human Neurofilament (H) promoter via a protein/protein interaction with a sequence specific DNA-binding protein.
MATERIALS AND METHODS
HeLa cell nuclear extracts (9) and bacterially expressed Spl-516C (10) were prepared as previously described. Vaccinia virus expressed full length Spl 778C was purchased from Promega.
Gel shift assays and DNase I protection assays were performed as previously described (9) . The following oligodeoxynucleotides were used: In gel shift competition assays, unlabeled competitor oligodeoxynucleotides were incubated with the nuclear extract for 10 min prior to addition of labeled probe. For supershift
• To whom correspondence should be addressed assays binding reactions were incubated with polyclonal rabbit anti-Spl (obtained from Stephen Jackson) or Pre-immune serum for 30 min at room temperature before radiolabeled probe was added to the binding reaction for 30 min.
RESULTS
Previously we identified multiple binding sites for nuclear proteins within the human NF(H) promoter (9) (Figure 1 ). Two typical G/C boxes were presumed to bind Spl. However two other sequences appeared unrelated to any known consensus sequence. One of these sites we called the Prox binding site due to its location closest to the NF(H) TATA box. The Prox binding site was centered around the sequence GGTTGGACC. Two sites more distally were centered around a pyrimidine (Pyr) tract (CCCTCCTCCCC). These Pyr sites formed an interrupted palindrome around one of the Spl sites. Pyr tract binding sites were subsequently found in the human NF(M) promoter (10) Numbering is relative to the start site of transcription (9) . A TATA homology at -29 and binding sites for nuclear factors which are discussed in the text are underlined. 'Pyr' refers to a pyrimidine tract which is present in two copies forming a palindrome as indicated by the arrows. 'Prox' refers to proximal binding site.
a related pyrimidine tract in the mouse NF(M) gene (CCCCTTCCCC) likely binds the same protein(s) (unpublished observations). Nuclear extracts from both neural and non-neural cell lines and mouse brain contain proteins that bind to the Prox and Pyr sites suggesting that these proteins may be ubiquitously distributed (9) . Gel shifts utilizing probes containing the Prox and the first Pyr tract sites produce one major and two minor complexes as seen in Figure 2 . Since neither the Prox or Pyr sequences looked like Spl sites (6), we were surprised that an Spl competitor could block binding to a probe containing only the Prox and 3' Pyr tract sites without Spl sites (Figure 2) . Surprisingly the Spl competitor blocked binding more effectively than either a Prox competitor which produced only a slight reduction in the major complex or a Pyr competitor which had no more effect on complex formation than non-specific competitors ( Figure 2 ).
Is Spl part of the complex?
Since in crude nuclear extracts a non-Spl G/C box binding protein(s) might be binding to the Prox and Pyr sites, it was necessary to confirm that Spl was contained in the complex. Therefore we performed gel shift (supershift) assays with a polyclonal anti-Spl antisera (gift of Dr S.Jackson). In gel shifts with HeLa nuclear extract and an Spl probe this antisera reduces probe binding and produces a supershifted complex (data not shown). As shown in Figure 3 , in a binding reaction pre-incubated with the Spl antibody before addition of probe, binding to the two upper complexes was reduced or eliminated and a supershifted complex appeared. This result confirmed that HeLa Spl or an immunologically very closely related protein was part of the complex. However the lack of effect of the Spl antibody •i - Nucleic Acids Research, 1992, Vol. 20, No. 23 6283 on the faster migrating complex suggested that a non-Spl protein also formed part of the complex.
Can Spl bind to the Pyr and/or Prox sequences?
To investigate this question we determined if Spl could bind to the Prox and/or Pyr tract sequences in DNase I footprints. Both HeLa and PC 12 nuclear extracts protect three major footprints on the human NF(H) promoter (9) . A proximal region containing the Prox binding site is separated by a prominent DNase I hypersensitive site (Figure 4 ) from a more distal region which includes the first Pyr and adjacent Spl site. A second Spl site is protected more distally. Bacterially expressed Spl 516C contains the 516 C-terminal amino acids of Spl including the DNA binding domain and produces footprints with probes of the SV40 early region which are identical to those given by full-length Spl (5). As shown in Figure 4 , bacterially expressed Spl 516C did not protect the proximal region and had at most a minimal effect over the Pyr site even at levels in several fold excess to those needed to protect the two G/C box containing Spl sites. Similar results were subsequently obtained in DNase I footprints with full-length vaccinia virus expressed Spl 778C (data not shown). Spl 778C also showed little if any detectable binding to probes containing the Pyr or Prox sites in gel shifts although both probes produce distinct complexes with HeLa extracts (See Figures 5 and 6 ). We have also found that neither Spl 516C or 778C binds to the pyrimidine tract in the human NF(M) promoter (10). 3 and 4) . Cl in Figure 5A ) appeared to be non-specific since it was unaffected by cold Prox competitor. However Prox competitor blocked binding to two other specific complexes ( C2 and C3). An Spl competitor reduced the upper C3 complex but had no effect on the lower Cl complex. Other competitors including NF-1 and Pyr tract competitors had no effect on either complex. These results implied that Spl was part of the C3 complex. We next performed supershift assays and found that the C3 but not the C2 complex was reduced and slightly supershifted by Spl antibody ( Figure 5B ). This effect occurred whether antibody was added before (as in Figure 5B ) or after (data not shown) protein binding to probe. In a complementary study we tested whether adding exogenous Spl to a HeLa extract would enhance the C3 complex. At sub-saturating levels of nuclear extract, adding exogenous Spl to the binding reaction enhanced the C3 but had no effect on the C2 complex ( Figure 5C ). Thus a non-Spl protein (Prox) must form the Cl complex while likely a combination of Spl and Prox form C3. Since Spl alone cannot bind to the Prox site (see Figure 5C and above) these data argue that Spl is targeted to the Prox site through protein/protein interactions with the Prox site binding protein.
Spl is targeted to the Prox binding site
Gel shifts performed with a Pyr site probe produced one major complex that was unaffected by an Spl competitor ( Figure 6A ). In supershift assays, a non-specifically shifted band was seen with both the anti-Spl and pre-immune serum, but no effect was seen on the major specifically shifted band ( Figure 6B ). As noted above purified HeLa Spl 778C showed little if any affinity for a Pyr site probe ( Figure 6B ). Thus Spl does not bind to the Pyr tract or interact with the protein(s) that bind there.
DISCUSSION
These experiments show that Spl can be targeted to a region of the human NF(H) promoter which lacks an Spl binding site. Targeting likely occurs through a separate protein (Prox) which binds around the sequence GGTTGGACC. Supershift data with an Spl antibody demonstrated that Spl is part of the Prox binding complex. However Spl does not bind to the Prox site in gel shifts or DNase I footprints. In gel shifts a distinct 'Prox' complex can be competed by a Prox but not by an Spl competitor. This complex does not supershift with Spl antibody. Thus the Prox binding protein is not a cofactor which allows Spl to recognize an atypical binding site but rather a separable DNA binding protein.
Spl contains a zinc finger DNA binding domain as well as a glutamine rich transcriptional activation domain (11, 12) and is phosphorylated upon DNA binding (13) . It must also contain regions for protein/protein interactions with transcriptional coactivators (7, 8) . Spl must as well contain a region for protein/protein interactions with the NF(H) Prox binding protein. Spl has been shown to complex with the E2 transcription factor of bovine papillomavirus, itself a sequence specific DNA-binding protein (14) . This interaction can target E2 to a promoter lacking E2-binding sites. However to our knowledge it has not been previously shown that Spl can be targeted to a promoter lacking a functional Spl binding site.
The Prox/Spl interaction could serve as a mechanism for recruiting a strong transcriptional activator such as Spl into a promoter which lacks Spl binding sites. Possibly recruitment of other sequence specific DNA-binding proteins into the transcription complex occurs through intermediary proteins as well. Such interactions could add an additional level of complexity to the combinatorial regulation of transcription. However it is unclear why this mechanism would be used in the NF(H) promoter which contains functional Spl binding sites just upstream of the Prox site (see Figure 1) .
Prior studies showed that in transfected cells the Prox site alone linked to the NF(H) TATA box activates transcription poorly being possibly no more active than the TATA box alone (9) . Thus targeting Spl to the Prox site may not by itself have great functional significance. However linking the adjacent Pyr site to the Prox site produced a strong synergistic activation of transcription which was 5 -10 fold greater than the activation seen with either site alone (9) . Possibly only when all three proteins, ie. Prox, Spl and the Pyr tract binding protein, interact does full transcriptional activation occur. The exact role each protein plays in such a complex is not known. Further studies on these possible interactions will require cloned Prox and Pyr binding proteins.
